Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial
Abstract Background The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested to be safe and effective for adult acute promyelocytic leukaemia (APL). As of 2010, the role of cytarabine (Ara-C) in APL was controversial. The aim of this study was to test the effic...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-018-4280-2 |
| _version_ | 1818765965068861440 |
|---|---|
| author | Li Zhang Yao Zou Yumei Chen Ye Guo Wenyu Yang Xiaojuan Chen Shuchun Wang Xiaoming Liu Min Ruan Jiayuan Zhang Tianfeng Liu Fang Liu Benquan Qi Wenbin An Yuanyuan Ren Lixian Chang Xiaofan Zhu |
| author_facet | Li Zhang Yao Zou Yumei Chen Ye Guo Wenyu Yang Xiaojuan Chen Shuchun Wang Xiaoming Liu Min Ruan Jiayuan Zhang Tianfeng Liu Fang Liu Benquan Qi Wenbin An Yuanyuan Ren Lixian Chang Xiaofan Zhu |
| author_sort | Li Zhang |
| collection | DOAJ |
| description | Abstract Background The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested to be safe and effective for adult acute promyelocytic leukaemia (APL). As of 2010, the role of cytarabine (Ara-C) in APL was controversial. The aim of this study was to test the efficacy and safety of ATRA and ATO in paediatric APL patients. Also, we assessed whether Ara-C could be omitted in ATO and ATRA- based trials in children. Methods We performed a randomized controlled trial in paediatric APL patients (≤14 years of age) in our hospital from May 2010 to December 2016. All of the patients were assigned to receive ATRA plus ATO for induction followed by one course of idarubicin (IDA) and ATO (28 days). The patients were then randomly assigned to receive two courses of daunorubicin (DNR, no- Ara-C group) or DNR + Ara-C (Ara-C group). All of the patients were followed with maintenance therapy with oral ATRA, 6-mercaptopurine, and methotrexate for 1.5 years. Results Among the 66 patients, 43 were male and 23 were female. All of the patients achieved complete remission (CR) with the exception of one who gave up the treatment. During induction therapy, all toxicity events were reversed after appropriate management. Thirty patients in the Ara-C group underwent 57 courses of treatment, and 35 patients in the no-Ara-C group underwent 73 courses of treatment. No significant differences in age, genders, white blood cell counts, haemoglobin levels, and platelet counts were found between the Ara-C and no-Ara-c groups. Greater myelosuppression and sepsis were observed in the Ara-C group during the consolidation courses. No patient died at consolidation, and only one patient relapsed. No differences were found in event-free survival, disease-free survival and overall survival between the two groups. Additionally, our analysis of the arsenic levels in the plasma, urine, hair and nails of the patients indicated that no significant accumulation of arsenic occurred after ATO was discontinued for 12 months. Conclusions Overall, ATO and ATRA are safe and effective for paediatric APL patients and Ara-C could be omitted when ATO is used for two courses. Trial registration ClinicalTrials.gov (NCT01191541, retrospectively registered on 18 August 2010). |
| first_indexed | 2024-12-18T08:26:28Z |
| format | Article |
| id | doaj.art-0daf47bc4af44f4a9513fb1a17dae6f6 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-18T08:26:28Z |
| publishDate | 2018-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-0daf47bc4af44f4a9513fb1a17dae6f62022-12-21T21:14:35ZengBMCBMC Cancer1471-24072018-04-011811810.1186/s12885-018-4280-2Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trialLi Zhang0Yao Zou1Yumei Chen2Ye Guo3Wenyu Yang4Xiaojuan Chen5Shuchun Wang6Xiaoming Liu7Min Ruan8Jiayuan Zhang9Tianfeng Liu10Fang Liu11Benquan Qi12Wenbin An13Yuanyuan Ren14Lixian Chang15Xiaofan Zhu16State Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Experimental Hematology, Department of Paediatrics Haematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background The combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested to be safe and effective for adult acute promyelocytic leukaemia (APL). As of 2010, the role of cytarabine (Ara-C) in APL was controversial. The aim of this study was to test the efficacy and safety of ATRA and ATO in paediatric APL patients. Also, we assessed whether Ara-C could be omitted in ATO and ATRA- based trials in children. Methods We performed a randomized controlled trial in paediatric APL patients (≤14 years of age) in our hospital from May 2010 to December 2016. All of the patients were assigned to receive ATRA plus ATO for induction followed by one course of idarubicin (IDA) and ATO (28 days). The patients were then randomly assigned to receive two courses of daunorubicin (DNR, no- Ara-C group) or DNR + Ara-C (Ara-C group). All of the patients were followed with maintenance therapy with oral ATRA, 6-mercaptopurine, and methotrexate for 1.5 years. Results Among the 66 patients, 43 were male and 23 were female. All of the patients achieved complete remission (CR) with the exception of one who gave up the treatment. During induction therapy, all toxicity events were reversed after appropriate management. Thirty patients in the Ara-C group underwent 57 courses of treatment, and 35 patients in the no-Ara-C group underwent 73 courses of treatment. No significant differences in age, genders, white blood cell counts, haemoglobin levels, and platelet counts were found between the Ara-C and no-Ara-c groups. Greater myelosuppression and sepsis were observed in the Ara-C group during the consolidation courses. No patient died at consolidation, and only one patient relapsed. No differences were found in event-free survival, disease-free survival and overall survival between the two groups. Additionally, our analysis of the arsenic levels in the plasma, urine, hair and nails of the patients indicated that no significant accumulation of arsenic occurred after ATO was discontinued for 12 months. Conclusions Overall, ATO and ATRA are safe and effective for paediatric APL patients and Ara-C could be omitted when ATO is used for two courses. Trial registration ClinicalTrials.gov (NCT01191541, retrospectively registered on 18 August 2010).http://link.springer.com/article/10.1186/s12885-018-4280-2Acute promyelocytic leukaemiaAll-trans retinoic acidArsenic trioxidePaediatricCytarabine |
| spellingShingle | Li Zhang Yao Zou Yumei Chen Ye Guo Wenyu Yang Xiaojuan Chen Shuchun Wang Xiaoming Liu Min Ruan Jiayuan Zhang Tianfeng Liu Fang Liu Benquan Qi Wenbin An Yuanyuan Ren Lixian Chang Xiaofan Zhu Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial BMC Cancer Acute promyelocytic leukaemia All-trans retinoic acid Arsenic trioxide Paediatric Cytarabine |
| title | Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial |
| title_full | Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial |
| title_fullStr | Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial |
| title_full_unstemmed | Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial |
| title_short | Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial |
| title_sort | role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all trans retinoic acid and arsenic trioxide a randomized controlled trial |
| topic | Acute promyelocytic leukaemia All-trans retinoic acid Arsenic trioxide Paediatric Cytarabine |
| url | http://link.springer.com/article/10.1186/s12885-018-4280-2 |
| work_keys_str_mv | AT lizhang roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT yaozou roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT yumeichen roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT yeguo roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT wenyuyang roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT xiaojuanchen roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT shuchunwang roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT xiaomingliu roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT minruan roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT jiayuanzhang roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT tianfengliu roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT fangliu roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT benquanqi roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT wenbinan roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT yuanyuanren roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT lixianchang roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial AT xiaofanzhu roleofcytarabineinpaediatricacutepromyelocyticleukemiatreatedwiththecombinationofalltransretinoicacidandarsenictrioxidearandomizedcontrolledtrial |